Neurocrine Total Assets vs Deferred Long Term Liab Analysis

NBIX Stock

USD 140.94 0.97 0.68%

Neurocrine Biosciences financial indicator trend analysis is infinitely more than just investigating Neurocrine Biosciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurocrine Biosciences is a good investment. Please check the relationship between Neurocrine Biosciences Total Assets and its Deferred Long Term Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Total Assets vs Deferred Long Term Liab

Total Assets vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurocrine Biosciences Total Assets account and Deferred Long Term Liab. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Neurocrine Biosciences' Total Assets and Deferred Long Term Liab is 0.54. Overlapping area represents the amount of variation of Total Assets that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Neurocrine Biosciences, assuming nothing else is changed. The correlation between historical values of Neurocrine Biosciences' Total Assets and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Assets of Neurocrine Biosciences are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Total Assets i.e., Neurocrine Biosciences' Total Assets and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

0.54

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Total Assets

Total assets refers to the total amount of Neurocrine Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Neurocrine Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from Neurocrine Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurocrine Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.At this time, Neurocrine Biosciences' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 63.8 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 22.9 M in 2024.

Neurocrine Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Other Liab	Other Assets
Total Assets		0.37	0.52	0.9	0.99	0.97	0.39	0.47	0.98	0.46	0.99	0.86	0.95	0.97	0.45	0.68	0.55	0.9	0.96	0.94	0.99	0.52	0.87	0.93	0.21	0.79
Short Long Term Debt Total	0.37		0.12	0.36	0.32	0.36	0.2	-0.45	0.33	0.26	0.36	0.23	0.46	0.28	0.7	0.42	-0.02	0.64	0.45	0.35	0.38	0.37	0.29	0.4	0.33	0.26
Other Current Liab	0.52	0.12		0.55	0.51	0.37	0.2	0.15	0.5	0.53	0.46	0.14	0.59	0.49	0.49	0.26	0.96	0.52	0.51	0.28	0.57	0.44	0.68	0.54	-0.17	0.6
Total Current Liabilities	0.9	0.36	0.55		0.88	0.91	0.58	0.42	0.95	0.23	0.88	0.81	0.86	0.92	0.37	0.41	0.53	0.8	0.89	0.89	0.91	0.81	0.74	0.89	0.23	0.6
Total Stockholder Equity	0.99	0.32	0.51	0.88		0.96	0.32	0.54	0.98	0.43	0.98	0.88	0.92	0.99	0.41	0.62	0.54	0.88	0.91	0.94	0.97	0.46	0.87	0.9	0.21	0.8
Property Plant And Equipment Net	0.97	0.36	0.37	0.91	0.96		0.37	0.57	0.98	0.34	0.98	0.91	0.86	0.96	0.29	0.59	0.37	0.81	0.91	1.0	0.92	0.53	0.81	0.86	0.19	0.74
Net Debt	0.39	0.2	0.2	0.58	0.32	0.37		-0.03	0.43	-0.37	0.36	0.34	0.41	0.38	0.21	0.21	0.22	0.4	0.5	0.36	0.41	0.74	0.13	0.41	0.38	-0.18
Retained Earnings	0.47	-0.45	0.15	0.42	0.54	0.57	-0.03		0.55	0.01	0.53	0.61	0.23	0.58	-0.45	0.02	0.22	0.06	0.3	0.58	0.39	0.02	0.48	0.27	-0.11	0.44
Accounts Payable	0.98	0.33	0.5	0.95	0.98	0.98	0.43	0.55		0.34	0.97	0.9	0.9	0.99	0.35	0.55	0.52	0.84	0.93	0.97	0.96	0.6	0.84	0.9	0.22	0.74
Cash	0.46	0.26	0.53	0.23	0.43	0.34	-0.37	0.01	0.34		0.42	0.1	0.55	0.33	0.52	0.66	0.54	0.5	0.49	0.28	0.49	-0.02	0.63	0.49	-0.27	0.84
Non Current Assets Total	0.99	0.36	0.46	0.88	0.98	0.98	0.36	0.53	0.97	0.42		0.86	0.9	0.96	0.37	0.67	0.48	0.86	0.94	0.97	0.95	0.47	0.86	0.86	0.16	0.78
Non Currrent Assets Other	0.86	0.23	0.14	0.81	0.88	0.91	0.34	0.61	0.9	0.1	0.86		0.74	0.92	0.15	0.39	0.19	0.69	0.75	0.93	0.82	0.41	0.63	0.76	0.43	0.55
Cash And Short Term Investments	0.95	0.46	0.59	0.86	0.92	0.86	0.41	0.23	0.9	0.55	0.9	0.74		0.9	0.63	0.73	0.63	0.96	0.95	0.83	0.98	0.57	0.83	0.98	0.26	0.76
Net Receivables	0.97	0.28	0.49	0.92	0.99	0.96	0.38	0.58	0.99	0.33	0.96	0.92	0.9		0.35	0.52	0.52	0.84	0.89	0.95	0.96	0.53	0.83	0.9	0.27	0.74
Common Stock Shares Outstanding	0.45	0.7	0.49	0.37	0.41	0.29	0.21	-0.45	0.35	0.52	0.37	0.15	0.63	0.35		0.51	0.47	0.74	0.5	0.25	0.52	0.33	0.39	0.57	0.31	0.39
Non Current Liabilities Total	0.68	0.42	0.26	0.41	0.62	0.59	0.21	0.02	0.55	0.66	0.67	0.39	0.73	0.52	0.51		0.34	0.72	0.78	0.56	0.68	0.13	0.64	0.63	0.07	0.63
Other Current Assets	0.55	-0.02	0.96	0.53	0.54	0.37	0.22	0.22	0.52	0.54	0.48	0.19	0.63	0.52	0.47	0.34		0.52	0.53	0.29	0.61	0.36	0.7	0.58	-0.07	0.6
Other Stockholder Equity	0.9	0.64	0.52	0.8	0.88	0.81	0.4	0.06	0.84	0.5	0.86	0.69	0.96	0.84	0.74	0.72	0.52		0.91	0.78	0.93	0.53	0.75	0.91	0.31	0.69
Total Liab	0.96	0.45	0.51	0.89	0.91	0.91	0.5	0.3	0.93	0.49	0.94	0.75	0.95	0.89	0.5	0.78	0.53	0.91		0.89	0.96	0.62	0.83	0.92	0.2	0.73
Property Plant And Equipment Gross	0.94	0.35	0.28	0.89	0.94	1.0	0.36	0.58	0.97	0.28	0.97	0.93	0.83	0.95	0.25	0.56	0.29	0.78	0.89		0.9	0.51	0.77	0.83	0.22	0.7
Total Current Assets	0.99	0.38	0.57	0.91	0.97	0.92	0.41	0.39	0.96	0.49	0.95	0.82	0.98	0.96	0.52	0.68	0.61	0.93	0.96	0.9		0.56	0.86	0.97	0.26	0.78
Short Term Debt	0.52	0.37	0.44	0.81	0.46	0.53	0.74	0.02	0.6	-0.02	0.47	0.41	0.57	0.53	0.33	0.13	0.36	0.53	0.62	0.51	0.56		0.33	0.64	0.16	0.19
Intangible Assets	0.87	0.29	0.68	0.74	0.87	0.81	0.13	0.48	0.84	0.63	0.86	0.63	0.83	0.83	0.39	0.64	0.7	0.75	0.83	0.77	0.86	0.33		0.79	0.09	0.89
Short Term Investments	0.93	0.4	0.54	0.89	0.9	0.86	0.41	0.27	0.9	0.49	0.86	0.76	0.98	0.9	0.57	0.63	0.58	0.91	0.92	0.83	0.97	0.64	0.79		0.27	0.75
Other Liab	0.21	0.33	-0.17	0.23	0.21	0.19	0.38	-0.11	0.22	-0.27	0.16	0.43	0.26	0.27	0.31	0.07	-0.07	0.31	0.2	0.22	0.26	0.16	0.09	0.27		-0.14
Other Assets	0.79	0.26	0.6	0.6	0.8	0.74	-0.18	0.44	0.74	0.84	0.78	0.55	0.76	0.74	0.39	0.63	0.6	0.69	0.73	0.7	0.78	0.19	0.89	0.75	-0.14

Click cells to compare fundamentals

Neurocrine Biosciences Account Relationship Matchups

Neurocrine Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.3B	1.7B	2.1B	2.4B	3.3B	3.4B
Short Long Term Debt Total	495.5M	412.3M	440.4M	262.9M	428.4M	449.8M
Other Current Liab	156.5M	147.1M	194.3M	292M	35.9M	42.1M
Total Current Liabilities	565.3M	186.5M	245.8M	537.7M	654.8M	687.5M
Total Stockholder Equity	636.9M	1.1B	1.4B	1.7B	2.2B	2.3B
Property Plant And Equipment Net	116.2M	127.4M	155.8M	145.6M	347.3M	364.7M
Net Debt	383.2M	(388.7M)	99.6M	169.4M	177.3M	186.2M
Retained Earnings	(1.1B)	(725.4M)	(635.8M)	(406.8M)	(157.1M)	(165.0M)
Accounts Payable	46.2M	39.4M	51.5M	76.3M	108.9M	114.3M
Cash	112.3M	801M	340.8M	262.9M	251.1M	131.9M
Non Current Assets Total	475M	718.5M	1.1B	915.2M	1.6B	1.7B
Non Currrent Assets Other	3.2M	6.4M	4.4M	25M	49.6M	52.1M
Cash And Short Term Investments	670.5M	801M	711.3M	989.3M	1.0B	1.1B
Net Receivables	126.6M	157.1M	185.5M	350M	439.3M	461.3M
Common Stock Shares Outstanding	95.7M	97.8M	97.9M	98.9M	101M	61.8M
Liabilities And Stockholders Equity	1.3B	1.7B	2.1B	2.4B	3.3B	3.4B
Non Current Liabilities Total	103.8M	422M	452.7M	123.2M	364.6M	382.8M
Other Current Assets	160.5M	215.2M	261.5M	464.2M	97.8M	61.5M
Other Stockholder Equity	1.8B	1.8B	2.0B	2.1B	2.4B	2.5B
Total Liab	669.1M	608.5M	698.5M	660.9M	1.0B	1.1B
Property Plant And Equipment Gross	116.3M	127.4M	155.8M	145.6M	430.3M	451.8M
Total Current Assets	831M	1.0B	972.8M	1.5B	1.6B	1.7B
Accumulated Other Comprehensive Income	1.4M	1.8M	(1.7M)	(7.9M)	7M	7.4M
Short Term Debt	408.8M	10.3M	16.5M	169.4M	170.1M	178.6M
Short Term Investments	558.2M	613.9M	370.5M	726.4M	780.5M	819.5M
Other Liab	17.1M	9.7M	12.3M	29.7M	34.2M	24.8M
Other Assets	59.1M	674M	319.5M	330.9M	380.5M	399.6M
Long Term Debt	388.5M	408.8M	317.9M	335.1M	385.4M	404.6M
Common Stock Total Equity	89K	91K	92K	100K	115K	67.8K
Common Stock	89K	91K	92K	100K	115K	69.6K
Property Plant Equipment	33.9M	41.9M	44.6M	58.6M	52.7M	55.4M
Current Deferred Revenue	(46.2M)	(10.3M)	(16.5M)	339.9M	390.9M	410.4M
Net Tangible Assets	228.1M	1.1B	1.4B	1.7B	1.9B	2.0B
Retained Earnings Total Equity	(1.1B)	(725.4M)	(635.8M)	(406.8M)	(366.1M)	(384.4M)
Capital Surpluse	1.8B	1.8B	2.0B	2.1B	2.4B	1.6B
Inventory	17.3M	28M	30.5M	35.1M	38.3M	40.2M
Non Current Liabilities Other	103.8M	104.1M	117.6M	29.7M	10.3M	9.8M
Long Term Investments	299.7M	227.1M	560.7M	401.5M	849.4M	891.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Neurocrine Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurocrine Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurocrine Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurocrine Biosciences Stock:

How To Invest In Neurocrine

Details

Is Neurocrine Stock a good investment?

Details

What is Neurocrine Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Neurocrine Stock analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.

	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Bonds Directory Find actively traded corporate debentures issued by US companies
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA

Is Neurocrine Biosciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.648

Earnings Share

3.68

Revenue Per Share

20.147

Quarterly Revenue Growth

0.226

Return On Assets

0.1008

The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neurocrine Total Assets vs Deferred Long Term Liab Analysis

Total Assets vs Deferred Long Term Liab

Total Assets vs Deferred Long Term Liab Correlation Analysis

Correlation Coefficient

Total Assets

Deferred Long Term Liab

Neurocrine Biosciences fundamental ratios Correlations

Neurocrine Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neurocrine Biosciences fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Neurocrine Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Net Receivables	+ 0.99	Total Stockholder Equity
Net Receivables	+ 0.99	Accounts Payable

Common Stock Shares Outstanding	- 0.45	Retained Earnings
Retained Earnings	- 0.45	Short Long Term Debt Total
Cash	- 0.37	Net Debt
Other Liab	- 0.27	Cash
Other Assets	- 0.18	Net Debt
Other Liab	- 0.17	Other Current Liab